KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

GoodRx Holdings (GDRX) EBT (2019 - 2025)

GoodRx Holdings (GDRX) has disclosed EBT for 7 consecutive years, with $14.2 million as the latest value for Q4 2025.

  • Quarterly EBT rose 24.4% to $14.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $56.5 million through Dec 2025, up 79.71% year-over-year, with the annual reading at $56.5 million for FY2025, 79.71% up from the prior year.
  • EBT hit $14.2 million in Q4 2025 for GoodRx Holdings, up from $6.1 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $19.6 million in Q2 2025 to a low of -$46.6 million in Q3 2023.
  • Historically, EBT has averaged -$49100.0 across 5 years, with a median of $4.7 million in 2021.
  • Biggest five-year swings in EBT: tumbled 2154.52% in 2022 and later surged 5588.74% in 2025.
  • Year by year, EBT stood at $5.9 million in 2021, then crashed by 180.83% to -$4.7 million in 2022, then tumbled by 419.18% to -$24.6 million in 2023, then soared by 146.31% to $11.4 million in 2024, then increased by 24.4% to $14.2 million in 2025.
  • Business Quant data shows EBT for GDRX at $14.2 million in Q4 2025, $6.1 million in Q3 2025, and $19.6 million in Q2 2025.